SG11201807885PA - Compositions and methods for making antibodies based on use of expression-enhancing loci - Google Patents

Compositions and methods for making antibodies based on use of expression-enhancing loci

Info

Publication number
SG11201807885PA
SG11201807885PA SG11201807885PA SG11201807885PA SG11201807885PA SG 11201807885P A SG11201807885P A SG 11201807885PA SG 11201807885P A SG11201807885P A SG 11201807885PA SG 11201807885P A SG11201807885P A SG 11201807885PA SG 11201807885P A SG11201807885P A SG 11201807885PA
Authority
SG
Singapore
Prior art keywords
international
rule
tarrytown
saw mill
expression
Prior art date
Application number
SG11201807885PA
Inventor
Robert Babb
Darya Burakov
Gang Chen
James Fandl
Yu Zhao
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201807885PA publication Critical patent/SG11201807885PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI 010111110101111 0 111 Iiv 1111 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/184832 Al 26 October 2017 (26.10.2017) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, C07K 16/00 (2006.01) C12N 15/90 (2006.01) KM, ML, MR, NE, SN, TD, TG). CO7K 16/46 (2006.01) (21) International Application Number: Declarations under Rule 4.17: PCT/US2017/028555 — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) (22) International Filing Date: — as to the applicant's entitlement to claim the priority of the 20 April 2017 (20.04.2017) earlier application (Rule 4.17(iii)) — of inventorship (Rule 4.17(iv)) (25) Filing Language: English (26) Publication Language: English Published: — with international search report (Art. 21(3)) (30) Priority Data: — with sequence listing part of description (Rule 5.2(a)) 62/325,400 20 April 2016 (20.04.2016) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US). (72) Inventors: BABB, Robert; c/o Regeneron Pharmaceu- ticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US). BURAKOV, Darya; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tar- rytown, NY 10591-6707 (US). CHEN, Gang; c/o Regen- eron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US). FANDL, James, P.; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US). = — (74) Agent: GROLZ, Edward, W.; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Suite 300, Garden City, NY 11530 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind ARIPO GH, of regional protection available): (BW, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, - TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, .4 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, N i MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, M co iv co 1-1 (54) Title: COMPOSITIONS AND METHODS FOR MAKING ANTIBODIES BASED ON USE OF EXPRESSION-ENHANCING IN LOCI 11 0 (57) : This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In partic- \" ular, the invention includes compositions and methods for improved expression of antigen-binding proteins including monospecific C and bispecifc antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing multiple expres- sion-enhancing locus.
SG11201807885PA 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci SG11201807885PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325400P 2016-04-20 2016-04-20
PCT/US2017/028555 WO2017184832A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Publications (1)

Publication Number Publication Date
SG11201807885PA true SG11201807885PA (en) 2018-10-30

Family

ID=58701851

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201807885PA SG11201807885PA (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci
SG10202010155YA SG10202010155YA (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202010155YA SG10202010155YA (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Country Status (15)

Country Link
US (2) US11512144B2 (en)
EP (1) EP3445781A1 (en)
JP (3) JP7096770B2 (en)
KR (2) KR20230098361A (en)
CN (2) CN109195986B (en)
AR (1) AR109451A1 (en)
AU (1) AU2017253241A1 (en)
BR (1) BR112018071283A2 (en)
CA (1) CA3015389A1 (en)
EA (1) EA201892010A1 (en)
IL (1) IL262266A (en)
MX (1) MX2018012868A (en)
SG (2) SG11201807885PA (en)
TW (1) TWI827531B (en)
WO (1) WO2017184832A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017253241A1 (en) * 2016-04-20 2018-09-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
KR20200103765A (en) * 2017-12-22 2020-09-02 제넨테크, 인크. Targeted integration of nucleic acids
JP2022514342A (en) * 2018-12-21 2022-02-10 ジェネンテック， インコーポレイテッド Targeted integration of nucleic acids
AU2020252840A1 (en) * 2019-04-02 2021-11-04 Chugai Seiyaku Kabushiki Kaisha Method of introducing target-specific foreign gene
WO2020264253A1 (en) 2019-06-26 2020-12-30 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
TW202330926A (en) 2021-10-18 2023-08-01 美商再生元醫藥公司 Controlled transcription of polynucleotides
WO2023069926A1 (en) 2021-10-18 2023-04-27 Regeneron Pharmaceuticals, Inc. Eukaryotic cells comprising adenovirus-associated virus polynucleotides
TW202334402A (en) 2021-10-18 2023-09-01 美商再生元醫藥公司 Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
TW202342755A (en) * 2021-12-22 2023-11-01 美商建南德克公司 Multi-vector recombinase mediated cassette exchange
WO2023238949A1 (en) * 2022-06-10 2023-12-14 富士フイルム株式会社 Method for producing cells, method for producing heteromultimeric protein, method for producing bispecific antibody, and method for producing vector set, mammalian cells, cho cells, and cell pool

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
AU2003237259B2 (en) 2002-05-29 2008-01-24 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
CA2504595A1 (en) 2002-11-14 2004-06-03 Lynne Krummen Intron fusion construct and method of using for selecting high-expressing production cell lines
CN101198698B (en) 2005-03-31 2014-03-19 中外制药株式会社 Process for production of polypeptide by regulation of assembly
PT1999154E (en) 2006-03-24 2013-01-24 Merck Patent Gmbh Engineered heterodimeric protein domains
RS52176B (en) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. High affinity antibodies to human il-6 receptor
US20100105042A1 (en) 2006-12-21 2010-04-29 Smithkline Beecham Corporation Novel methods
WO2008089396A1 (en) 2007-01-19 2008-07-24 Invitrogen Corporation Compositions and methods for genetic manipulation and monitoring of cell lines
NZ614857A (en) 2007-03-29 2015-04-24 Genmab As Bispecific antibodies and methods for production thereof
ES2522615T3 (en) * 2007-06-04 2014-11-17 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
PL3279326T3 (en) 2009-06-02 2021-03-08 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
KR101904065B1 (en) 2009-06-26 2018-10-04 리제너론 파마슈티칼스 인코포레이티드 Readily isolated bispecific antibodies with native immunoglobulin format
SG10201408401RA (en) 2009-09-16 2015-01-29 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
AU2010297011A1 (en) 2009-09-18 2012-04-12 Selexis S.A. Products and methods for enhanced transgene expression and processing
SG10201800757TA (en) 2010-04-20 2018-02-27 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
EP2606064B1 (en) 2010-08-16 2015-02-25 NovImmune S.A. Methods for the generation of multispecific and multivalent antibodies
TW201823460A (en) 2012-05-29 2018-07-01 美商再生元醫藥公司 Production cell line enhancers
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
TWI745610B (en) 2012-11-14 2021-11-11 美商再生元醫藥公司 Recombinant cell surface capture proteins
TWI682941B (en) 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI728373B (en) 2013-12-23 2021-05-21 美商建南德克公司 Antibodies and methods of use
TWI701042B (en) 2014-03-19 2020-08-11 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
US9816110B2 (en) 2014-10-23 2017-11-14 Regeneron Pharmaceuticals, Inc. CHO integration sites and uses thereof
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
AU2017253241A1 (en) * 2016-04-20 2018-09-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci

Also Published As

Publication number Publication date
CN116515757A (en) 2023-08-01
JP2021164479A (en) 2021-10-14
JP2019515666A (en) 2019-06-13
US20190233544A1 (en) 2019-08-01
JP7096770B2 (en) 2022-07-06
TW201803986A (en) 2018-02-01
WO2017184832A1 (en) 2017-10-26
IL262266A (en) 2018-11-29
CN109195986B (en) 2023-01-03
JP2024023449A (en) 2024-02-21
EP3445781A1 (en) 2019-02-27
EA201892010A1 (en) 2019-03-29
AU2017253241A1 (en) 2018-09-20
KR102547738B1 (en) 2023-06-26
BR112018071283A2 (en) 2019-02-12
KR20230098361A (en) 2023-07-03
US11512144B2 (en) 2022-11-29
US20230130799A1 (en) 2023-04-27
TWI827531B (en) 2024-01-01
SG10202010155YA (en) 2020-11-27
MX2018012868A (en) 2019-03-11
AR109451A1 (en) 2018-12-12
CA3015389A1 (en) 2017-10-26
CN109195986A (en) 2019-01-11
KR20180134893A (en) 2018-12-19

Similar Documents

Publication Publication Date Title
SG11201807885PA (en) Compositions and methods for making antibodies based on use of expression-enhancing loci
SG11201807881VA (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
SG11201810327XA (en) Single domain serum albumin binding protein
SG11201807187XA (en) Binding members to pd-l1
SG11201909203WA (en) Tissue selective transgene expression
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201811270WA (en) Systems and methods for trajectory determination
SG11202000073XA (en) Anti-cd8 antibodies and uses thereof
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201909011PA (en) Niraparib compositions
SG11201810777WA (en) Purification of multispecific antibodies
SG11201906341XA (en) Improved serum albumin binders
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201808398PA (en) Cell line for recombinant protein and/or viral vector production
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201807794VA (en) Naphthene-containing distillate stream compositions and uses thereof
SG11201807038UA (en) Rodents having a humanized tmprss gene
SG11201810757YA (en) Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
SG11201810525XA (en) Anti-gitr antibodies and uses thereof